Can a new pill wipe out hidden myeloma after transplant?

NCT ID NCT05434689

Ongoing Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding iberdomide (a new oral drug) to standard treatments can eliminate tiny amounts of myeloma cells that remain after a stem cell transplant. About 80 adults with multiple myeloma who still have detectable cancer cells after transplant will receive one of several drug combinations. The goal is to see if these combinations can make the cancer undetectable and keep it away longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iberdomide (a new oral drug) combined with daratumumab, dexamethasone, or carfilzomib
What this could lead to: If successful, this could offer a way to eliminate remaining cancer cells after transplant, potentially leading to longer remission and better disease control for multiple myeloma patients.
What could go wrong: This is an early-phase trial with only 80 participants, so results may not apply broadly. The drug combinations may cause side effects or fail to clear residual disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Ohio State University Medical College

Columbus, Ohio, 43210, United States
Oregon Health and Science University

Portland, Oregon, 97239, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States
University of Wisconsin

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.